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Introduction: 20
Hemagglutinin (HA) is a homotrimeric molecule that is the major surface glycoprotein of 21 influenza virus.
Each monomer consists of two disulfide-linked glycosylated 22 polypeptides, HA1 and HA2, that are generated by proteolytic cleavage (15). These 23 polypeptides make up two structurally distinct domains, a globular head composed of 24 part of the HA1, and a stalk structure composed of portions of HA1 and all of HA2 (27) . 25
These domains are involved in two essential functions for the initiation of viral infection. 26
The globular head domain contains a sialic acid binding pocket that mediates virus 27 attachment to the host cell (18), whereas the fusion peptide, located in the HA2 region 28 of the stalk domain, induces pH-triggered membrane fusion between the viral envelope 29 and the endosomal membrane of the cell. These functions allow the virus to enter the 30 host cell and release genetic material so that replication, transcription, and translation 31 of the viral genome -and the subsequent production of progeny virions -can occur. 32
The globular head domain of the HA is also the major antigenic component on the 33 surface of the virus. A large percentage of the antibodies generated after infection by 34 influenza viruses are directed against specific antigenic sites located in the globular head 35 domain of the HA (15). Earlier studies from our laboratory have shown that foreign B-36 cell epitopes, either from another HA subtype (10) or another unrelated virus (9, 12) can 37 be introduced into the antigenic sites of the head domain of the HA and infectious 38 influenza viruses can be generated. Vaccination with such chimeric viruses can induce 39 an immune response against both parental viruses. 40 4 Previously, we had used a highly conserved disulfide bond (Cyc52-Cyc277, H3 41 numbering) that separates the stalk and head domains to construct headless HA 42 immunogens (20) . We then hypothesized that we could use the same disulfide bond as 43 a demarcation point to generate influenza viruses expressing chimeric HAs (cHA) (100, 20, 4, 0.8, 0 .16 and 0.032 ug/ml) of mAb 156 KB2, a broadly neutralizing anti-HA stalk antibody generated in our laboratory (data not 157 shown) for 60 minutes in a total volume of 240 uL at room temperature. A confluent 158 layer of MDCK cells in 6-well plates was washed twice with PBS and then incubated with 159 the antibody-virus mixture for 40 minutes at 37°C. A TPCK-trypsin agar overlay 160 supplemented with antibody at the above-described concentrations or no antibody was 161 then added to each well after the inoculum had been aspirated off. Plates were 162 incubated for 2 days at 37°C. Plaques were then visualized by immunostaining (1, 19) 163 with anti-influenza A NP antibody HT103. 164 10 Pseudotype particle neutralization assay. The procedure for pseudotype 165 particle production was the same as described above, using the cHA construct that is 166 comprised of either a VN/04 (H5) or a Cal/09 (H1) head and a PR8 (H1) stalk with the 167 influenza B/Yamagata/16/88 virus NA. Particles were then incubated with different 168 concentrations of mAb KB2 at 5 fold dilutions from 100 to 0.032 µg/mL. Then, these 169 mixtures were added to MDCK cells. Transductions proceeded for 6 hours before cells 170 were washed and fresh medium was placed over cells. All transductions using 171 pseudotype particles were performed in the presence of 1 μg/mL polybrene (Sigma, St. 172
Louis, MO) (23). Forty-eight hours post-transduction, luciferase assays were performed 173 in order to assay the degree in which entry was blocked by mAb KB2. 174 11
Results: 175
Generation of chimeric hemagglutinins 176
We generated an alignment of influenza A virus HA sequences of the H1, H3, H5 and H7 177 subtypes used in this study in order to see if the cysteine residues forming the Cys52-178
Cys277 disulfide bond were conserved. Because these cysteine residues are highly 179 conserved across HA subtypes, for both group 1 and group 2 HAs, we hypothesized that 180 we could use this bond as a delineating point between the head and stalk domains. By 181 defining the sequence between Cys52 and Cys277 as the head region, and the 182 remainder of the molecule as the stalk, we rationalized that we could engineer 183 constructs that encode novel head and stalk combinations from a variety of HA subtypes 184 ( Figure 1A and B) . 185
The degree of amino acid identity that exists between the stalk regions of hemagglutinin 186 subtypes further encouraged us that the swapping of head domains might be possible. 187
Higher percentages of amino acid identity were seen in the stalk domains across all 188 subtypes, compared to the head domains ( Figure 1C) . 189
All 16 subtypes of influenza HA are classified into two phylogenetic groups (15). 190
Because we saw higher percentages of amino acid identity within stalk regions of a 191 particular group ( Figure 1C ), and because we had success in generating one cHA virus 192 that contained head and stalk domains from group 1 viruses (16), we attempted to 193 make intra-group cHAs. For group 1, we generated two chimeric hemagglutinin 194 constructs that encode either the pandemic H1 Cal/09 HA or VN/04 globular head 195 12 domain with the stalk region from PR8 (H1) HA (cH1/1 and cH5/1, respectively) ( Figure  196 1B). We applied a similar strategy to generate a chimeric HA that expressed head and 197 stalk domains from different group 2 influenza strains: the head from Alb/01 (H7, group 198 2) and the stalk region from Perth/09 (H3, group 2) HA (cH7/3) ( Figure 1B antibodies, respectively. Using this method, we were able to detect cell surface 207 expression of all four chimeric constructs ( Figure 2A ). However, compared to the wild 208 type PR8 HA less surface protein expression was detected for the cH1/1 construct, 209 which could be attributed to the inherent character associated with the head domain of 210 the Cal/09 HA or a lower transfection efficiency for this chimeric DNA construct. In 211 addition, it is of note that there were differences in the cell surface expression pattern 212 for the cH7/3 and cH5/3 constructs. This "double peak" expression pattern was 213 observed only in transfection conditions, and was reproducible. It was not detected 214 upon infection with either cH7/3 or cH5/3-expressing recombinant viruses ( Fig. 2A) . 215
Therefore, these data indicate that the cHAs can be transported through the Golgi 216 complex to the cell surface. 217
on July 8, 2017 by guest http://jvi.asm.org/ 13 Next, we examined the entry characteristics of the different cHAs through transduction 218 of MDCK cells with retroviral pseudotype particles that contained a luciferase reporter 219 construct and expressed the cHA and wild-type B/Yamagata/16/88 virus NA on the 220 particle surface. The entry efficiency mediated by the cHA proteins was detected by the 221 luciferase read-out. Comparable levels of pseudotype particle-mediated luciferase 222 expression were observed for cH5/1, cH7/3 and cH5/3 chimeric HAs and the 223 corresponding wild type proteins ( Figure 2B ). Particles encoding the cH1/1 HA 224 expressed lower luciferase levels compared to the other HA constructs, which could be 225 due to either the lower expression of the cH1/1 in the producer cell line and hence 226 fewer HA trimers per particle or the less efficient entry properties of the cH1/1 HA. It is 227 also possible that when normalizing the pseudotype particles to 4 hemagglutinin units, 228 the actual amount of pseudotype particles may vary due to differences in binding to red 229 blood cells. 230
Generation of recombinant influenza viruses bearing chimeric hemagglutinins 231
Because we had determined that our cHA constructs were efficiently expressed and 232 transported to the cell surface, we wanted to ascertain whether a recombinant 233 influenza virus that encodes a cHA could be rescued. Using previously published 234 protocols (7, 8), we succeeded in generating viruses containing the different cHAs. The 235 resulting viruses were plaque purified, amplified in 10 day old embryonated eggs and 236 the chimeric segments were analyzed by RT-PCR and sequenced. In all cases, the virus 237 14 was found to have the expected chimeric HA segment and no other HA segment (data 238 not shown). 239
We further confirmed the presence of the cHAs in rescued viruses by Western blot and 240 indirect immunofluorescence of infected cells ( Figure 3A and B) . MDCK cells were 241 infected with rWT PR8, wild-type Perth/09, cH1/1, cH5/1, cH7/3 and cH5/3 viruses 242 ( Figure 3A and 3B). cH1/1 and cH5/1 chimeric HA proteins were detected in the 243 corresponding samples using antibodies reactive against the head domains of Cal/09 244 (H1) HA (29E3) (11) or VN/04 (H5) HA (mAb #8) (19) respectively ( Figure 3A ). Using 245 12D1, a pan-H3 anti-stalk mAb (25), we could observe comparable expression levels 246 among the cH7/3, cH5/3 and wild type Perth HA. The wild type Perth HA showed a 247 slower migration on the gel that is likely due to a higher number of glycosylation sites in 248 the globular head domain. We confirmed that the correct HA head domain was 249 expressed atop an H3 stalk by using anti-H7 polyclonal (NR-3152) or anti-H5 monoclonal 250 antibodies (mAb #8) on cH7/3 or cH5/3 infection samples, respectively. Positive bands 251 were detected in both cases. 252
For the immunofluorescence study, the infection conditions were similar to those used 253 for Western blot analysis. Infected cells were stained with corresponding antibodies as 254 used in Figure 3A . All infected cells showed the expected expression of the chimeric and 255 wild type HAs, as well as of the influenza A virus NP ( Figure 3B) . cH5/1 and cH5/3 viruses displayed comparable replication kinetics to that of rWT PR8 261 virus. cH7/3 virus grew to similar peak titers as rWT PR8 at 48 hpi (1X10 9 PFU/mL), 262 though there was a 2 log reduction in viral titer compared to the rWT PR8 virus at 9 hpi. 263
The cH1/1 virus was attenuated as compared to the rWT PR8 virus, as shown by reduced 264 viral titers at all time points. Nonetheless, cH1/1 virus reached a respectable peak titer 265 of approximately 10 8 PFU/mL. The Perth/09 Wild type virus grows to comparable peak 266 titers in embryonated eggs (data not shown). 267
The plaque phenotype of each of the chimeric viruses was also evaluated in MDCK cells. 268
All viruses formed comparable sized plaques as shown in Figure 4B . These data together 269 confirm that the chimeric HA constructs fold correctly and are biologically functional. 270
Stalk specific antibodies can neutralize cHA-expressing viruses and pseudoparticles 271
Finally, we wanted to test whether stalk-specific antibodies were able to neutralize our 272 newly generated recombinant viruses expressing cHAs. We performed plaque reduction 273 assays in the presence of mAb KB2, an HA-stalk specific antibody with broad group 1 274 reactivity generated in our laboratory, or without antibody. We were able to show that 275 mAb KB2 neutralizes all cHA-expressing viruses with similar efficiency and in a dose 276 dependent manner. At 100ug/mL, mAb KB2 was able to completely neutralize cH1/1 277 on July 8, 2017 by guest http://jvi.asm.org/ Downloaded from 16 and cH5/1 viruses with 100% efficiency, with some neutralizing activity at 278 concentrations as low as 4ug/mL ( Figure 5A) . 279
We confirmed these results using a pseudotype particle inhibition assay with mAb KB2. 280
Pseudotype particles expressing cH1/1 or cH5/1 and influenza B virus NA were added to 281 MDCK cells in the presence of mAb KB2, or without antibody. Forty-eight hours post-282 transduction, supernatant was collected and luciferase activity was analyzed. As 283 expected, mAb KB2 blocked the entry of cH1/1 and cH5/1 pseudotype particles in a 284 dose dependent manner at concentrations above 4ug/mL. While a lower concentration 285 of mAb KB2 was sufficient to inhibit entry of pseudotype particles compared to 286 concentrations used in the plaque reduction assay, this was an expected result due to 287 the assumed lower incorporation of HA trimers on the surface of pseudotype particles 288 (3). This phenomenon of different neutralizing potencies of mAbs in assays that involve 289 whole virus versus pseudotype particles has been appreciated in other studies (3, 21) . 290
Discussion 292
Using the conserved disulfide bond Cys52-Cys277 which defines the border between the 293 head and stalk domains, we developed a strategy to generate influenza viruses with 294 chimeric HA proteins that express different HA globular head and stalk domain 295 combinations. The constructs included the combination of heads and stalks within 296 group 1 (cH1/1 and cH5/1) and group 2 (cH7/3) or between the two HA groups (cH5/3). 297
All constructs were expressed on the cell surface and retained fusion activity. The 298 generation of recombinant viruses bearing the cHAs further validated that the HAs 299 folded correctly and retained biological functions. Furthermore, we have demonstrated 300 cHA-expressing recombinant viruses and pseudoparticles can be neutralized using 301 monoclonal antibodies with known reactivity to HA stalk domains. 302
While we were able to detect surface expression and fusion capability for all cHAs, it is 303 interesting to note that the surface expression level of cH1/1 HA was approximately two 304 fold lower than that of the wild type PR8 HA ( Figure 2A) ; the fusion activity was also less 305 efficient ( Figure 2B ). Despite these minor deficiencies, we were able to generate 306 recombinant viruses with the cH1/1 HA and the resulting virus showed only a one log 307 lower peak titer than wild type PR8 ( Figure 4A ). It is known that Cal/09 wild type virus 308 grows poorly in eggs, with an early report implicating two amino acid substitutions with 309 this phenotype (K119E and A186D) (2). Therefore, the attenuation of cH1/1 virus is 310 demonstrates that a cHA could be generated using combinations of heads and stalks 315 within or between the two defined HA phylogenetic groups. Although we were able to 316 rescue these recombinant viruses, it is possible that certain head and stalk combinations 317
would not be able to be rescued. An inherent difference of compatibility might exist 318 between the heads and stalks of different HA subtypes (or viral variants) . antibodies that bind to epitopes on the influenza virus HA stalk domain (4, 5, 22, 24, 28 
